In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals by Eduardo Zimmer et al.
Translational 
Neurodegeneration
Zimmer et al. Translational Neurodegeneration 2014, 3:6
http://www.translationalneurodegeneration.com/content/3/1/6REVIEW Open AccessIn vivo tracking of tau pathology using positron
emission tomography (PET) molecular imaging in
small animals
Eduardo Rigon Zimmer1,2,3†, Antoine Leuzy1,2†, Venkat Bhat4, Serge Gauthier1 and Pedro Rosa-Neto1,2*Abstract
Hyperphosphorylation of the tau protein leading to the formation of neurofibrillary tangles (NFTs) is a common
feature in a wide range of neurodegenerative diseases known as tauopathies, which include Alzheimer’s disease
(AD) and the frontotemporal dementias (FTDs). Although heavily investigated, the mechanisms underlying the
pathogenesis and progression of tauopathies have yet to be fully understood. In this context, several rodent
models have been developed that successfully recapitulate the behavioral and neurochemical features of tau
pathology, aiming to achieve a better understanding of the link between tau and neurodegeneration. To date,
behavioral and biochemical parameters assessed using these models have been conducted using a combination of
memory tasks and invasive methods such as cerebrospinal fluid (CSF) sampling or post-mortem analysis. Recently,
several novel positron emission tomography (PET) radiopharmaceuticals targeting tau tangles have been developed,
allowing for non-invasive in vivo quantification of tau pathology. Combined with tau transgenic models and micro-
PET, these tracers hold the promise of advancing the development of theoretical models and advancing our under-
standing of the natural history of AD and non-AD tauopathies. In this review, we briefly describe some of the most
important insights for understanding the biological basis of tau pathology, and shed light on the opportunity for
improved modeling of tau pathology using a combination of tau-radiopharmaceuticals and animal models.
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Tau is a microtubule-associated protein (MAP) responsible
for the maintenance and promotion of cell microtubule
stability. In the human brain there are six tau isoforms
generated by in or out exons splicing and expressed as
three repeat (3R) and four repeat (4R) isoforms. In the
normal human brain these isoforms are present at similar
levels [1]. Several serine (Ser) and threonine (Thr) phos-
phate acceptor residues (almost 90 sites in the longest form
of human tau) are the main regulators of tau functioning
and are a target for a wide range of brain kinases involved
in crucial signaling pathways owing to the high availability
of these phosphorylation sites [2].* Correspondence: pedro.rosa@mcgill.ca
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unless otherwise stated.There are at least four key kinases regulating tau phos-
phorylation states: glycogen synthase kinase-3B (GSK3-B),
cyclin-dependent kinase 5 (CDK5), cAMP-dependent
protein kinase (PKA) and microtubule-associated regula-
tory kinase (MARK). In addition to mediating axonal
cytoskeletal stability, tau is involved in axonal develop-
ment—including axonogenesis, polarization, outgrowth
and myelination [3]—as well as in neuronal plasticity and
the integration of microtubule functions with interneuronal
signaling pathways [3,4].
The fine-tuning of tau phosphorylation also depends
on protein phosphatase activities, in particular protein
phosphatase 2A (PP2A). The major phosphatase in the
human brain [5], PP2A accounts for the overwhelming
majority of tau dephosphorylation. In fact, tau homeosta-
sis depends on kinase/phosphatase activities and is of vital
importance for the maintenance of microtubule stability,
dynamics, as well as neuronal viability (Figure 1a).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Tau protein physiological functions and pathological role. a) Physiological function: Tau protein promotes assembly and stabilization of
microtubule architecture. Tau phosphorylation sites and isoforms are in charge of regulating tau function; b) Pathological role: Aberrant phosphorylation
at various serine/threonine sites attenuates tau binding, which results in microtubule destabilization followed by accumulation in paired helical filaments
(PHFs) and formation of insoluble aggregates (neurofibrillary tangles; NFTs).
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Aberrant phosphorylation of tau leads to disruption of
microtubule stability and neurodegeneration. Phosphor-
ylation in the residues Ser199/Ser202/Thr205 (AT8),
Thr212/Ser214/Thr217 (AT100), Thr231/235 (AT180) and
Ser396/Ser404 (PHF-1) are invariably abnormal in patho-
logical processes involving tau [6] (Figure 1b). Abnormally
phosphorylated tau undergoes misfolding and aggregation,
which constitutes a widespread feature among neurode-
generative diseases, including Alzheimer’s disease (AD) and
Frontotemporal dementias (FTDs) [7,8].
In these diseases, the so-called tauopathies, tau deposits
are commonly found in the cell bodies and neuronal
dendrites, assuming a fibrillar conformation known as
neurofibrillary tangles (NFTs) [9] (Figure 2a). In AD, NFT
formation follows a well-characterized pattern of propaga-
tion, first described by Braak and Braak. The Braak staging
follows the topographical evolution of the disease by
means of six stages, which demonstrate the spread of tau
pathology from the transentorhinal layer (I-II) toward lim-
bic (III-IV) and isocortical areas (V-VI) [10]. Additionally,
several studies have shown the degree of tau pathology to
correlate with synaptic dysfunction and brain atrophy, as
well as the severity of cognitive decline [11-13]. Import-
antly, while in AD tangles are constituted of equimolar 3R
and 4R isoforms, FTD variants express predominantly 3R
or 4R isoforms [14].
The main challenge with respect to defining the role
of tau pathology in human neurodegenerative conditions
is the co-existence of multiple pathology types. For ex-
ample, in AD it is hard to develop theoretical models
that allow for predictions regarding the evolution of tau
pathology since amyloidosis is also present to an important
degree. To overcome the effect of multiple pathologies,
animal models expressing a single human tau mutation or
displaying aberrant tau phosphorylation can be used as amethod of choice to achieve an improved understanding
of tau biology, pathology and the mechanisms underlying
its spread throughout the brain.
Genetic and chemical models of tau pathology
The use of rodents for recapitulating human neurode-
generative diseases has been unquestionable in providing
new insights at a mechanistic level, with various genetic
and chemical models capable of mimicking different fea-
tures of tau pathology [15]. More specifically, the major-
ity of transgenic models are constructed based on tau
pathogenic mutations from frontotemporal dementia
with parkinsonism-17 (FTDP-17), producing 4R pathology
[16-18]. In addition, transgenic models using non-mutated
human truncated tau are able to recapitulate neurofib-
rillary degeneration [19]. Recent advances, aiming to better
model neurodegenerative changes seen in AD, pieced
together mutated human amyloid precursor protein (hAPP)
and wild-type human tau (without pathogenic mutation),
producing a model displaying amyloid plaques and NFTs
containing both 3R and 4R isoforms [20].
Importantly, transgenic models expressing human tau
are capable of reproducing NFT formation [21,22]. In con-
trast, genetic models lacking human tau expression such as
p25-transgenic mice, which overexpress the human activa-
tor of CDK5 kinase, [23,24] and chemical-induced models
[25,26] lead to hyperphosphorylated tau in brain regions
rich in tau expression, but not to NFT formation (for re-
view of tau rodent models see http://www.alzforum.org/
research-models).
Tau models have been employed for analyzing mecha-
nisms, pathophysiology, behavior, and also for testing
novel therapeutic strategies. Currently, behavioral tasks,
analyzed by several memory paradigms, such as the
Morris water maze (spatial memory), object recognition
task (recognition memory) and Y or T-maze (working
Figure 2 Neuropathological mechanisms possibly involved in tauopathies and expected tracking of tau spreading by imaging agents
in rodent models. a) Pathological events (blue box) that contribute to tau hypherphosphorylation (purple box), microtubule detachment (green box),
aggregation of paired helical filaments (PHFs) containing β-sheet structures (yellow box) and formation of neurofibrillary tangles (NFTs) containing the
binding pocket for tau tracers (red box); b) Expected progression of tau pathology as shown by tau imaging agents based on previous findings in
AD-like mouse models using immunohistochemistry. The image represents a coronal view of a T1-weighted mouse brain structural magnetic
resonance imaging (MRI) image at bregma −2.88 mm.
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levels of tau and phospho-tau. Similar to humans, animal
cognition correlates with tau pathology quantified in post-
mortem tissue [25,27-29]. However, in terms of assessing
the role of tau burden on cognition, classic behavior-
pathology correlation methods are of limited use due their
invasiveness and intrinsic cross-sectional study designs.
In contrast, Positron Emission Tomography (PET) using
tau-imaging agents provides a unique opportunity to
observe the progression of tau pathology non-invasively
and longitudinally.
Tau imaging agents
Advances in radiopharmaceuticals have recently led to
novel tau-imaging agents, including [18 F]T807, [18 F]T808,
[18 F]THK523, [18 F]THK5105, [18F]THK5115 and
[11C]PBB3. In the following paragraphs, we briefly dis-
cuss the state-of-the-art of these compounds and what
lies ahead.
[18 F]T807 and [18 F]T808 probes show promising results
for tracking tau pathology in early clinical studies. In
addition, post-mortem autoradiography followed by im-
munohistochemistry shows co-localization between these
radiopharmaceuticals and phospo-tau antibodies [30,31].
Similar autoradiography studies with fluorine-tagged li-
gands THK523 (first-generation), THK5105 and THK5117
(second-generation) show high affinity for tau fibrils [32].
[18 F]THK523 shows specificity for tangles in studiesconducted in transgenic mice models harboring only amyl-
oid plaques or NFTs [33]. However, similarly to several [18
F] tracers, [18 F]THK523 shows an undesired high non-
specific retention in white matter (WM) that may obscure
cortical uptake. WM non-specific uptake reduces the
diagnostic sensitivity of numerous imaging agents. To
overcome this limitation, the second-generation of THK
tracers, [18 F]THK5105 and [18 F]THK5117, were optimized
for higher NFTcortical uptake and less WM retention [34].
The only tau radioligand labeled with carbon-11, [11C]
PBB3, shows striking specificity for NFT detection in
transgenic models overexpressing human tau mutation.
Despite its structural similarities with [11C]PiB, the [11C]
PBB3 data obtained in transgenic mice support specificity
for tau pathology. In humans, [11C]PBB3 shows cortical
uptake consistent with Braak staging. Indeed, positive
[11C]PBB3 and negative [11C]PiB characterized a cortico-
basal syndrome patient [35]. These tracers hold the prom-
ise of allowing for the in vivo detection and tracking of tau
pathology, and may prove of use in differentiating AD and
non-AD tauopathies. However, it is not entirely clear
whether a single tau-imaging agent will be useful to
quantify pathology underlying the entire spectrum of
tauopathies given the presence of molecular heterogeneity.
For example, it is commonly known in PET literature that
the interaction between an imaging agent and a molecular
target (e.g. a protein) occurs only if the binding pocket is
accessible to the imaging agent. Binding pocket availability
Table 1 Tau imaging agents: from basic to clinical
applications
Basic research The combination of Tau imaging agents and
transgenic models can allow for:
a) Non-invasive longitudinal tracking of tau
pathology
b) Longitudinal assessment of behavior as a
function of tau pathology
c) Determination of pharmacokinetic properties
d) Development of novel radiopharmaceuticals
e) Development of theoretical models regarding
progression of tau pathology
Clinical applications The use of Tau imaging agents in the clinical
approach can allow for:
a) Early diagnosis
b) Differential diagnosis
c) Follow-up of cognitive decline as function of
tau pathology progression
d) Monitoring of treatment effectiveness of
novel anti-tau and associated therapies
e) Development of theoretical models regarding
tau pathology progression
f) Estimation of sample size and endpoints in
the context of clinical trials
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which can be absent if the protein assumes an unusual
conformation. Consequently, the ability of tracers to bind
to NFTs may be affected by different post-translational
modifications such that a given radiotracer may be able to
bind NFTs but not to other ultrastructural tau conforma-
tions, such as straight (SF) or randomly coiled filaments
(RCFs). Additionally, tau expression as 3R and 4R isoforms
can strongly modulate the availability of binding pockets,
since these different isoforms can assume distinct structural
conformations.
In this context, the combination of tau tracers and
genetic manipulation to achieve transgenic rodent models
expressing human tau with a given conformation/isoform
may accelerate our understanding of the mechanisms
subserving tau-mediated neurodegeneration and clinical
progression across the spectrum of tauopathies.
Tracking tau pathology in small animals
Since only human tau protein assumes the structural con-
formation rendering NFTs, transgenic models expressing
human tau are sine-qua-non for testing new imaging agents
with high translation value for human diseases [9]. Further,
a high degree of homology and functional similarity is
observed between humans and rodents in brain areas
recognized as predilection sites for tau pathology, includ-
ing the hippocampus [36-38].
Tau transgenic models, combined with behavioral as-
sessment and in vivo imaging using microPET stands as a
unique strategy for establishing the clinico-pathological
correlations needed for testing the efficacy of novel
disease-modifying drugs. Additionally, in vivo tracking of
tau pathology in transgenic rodent models will provide
new insights with high translational value owing to the
spatiotemporal pattern of propagation similar to that ob-
served in human tauopathies [37] (Figure 2b). In addition
to occupying an important role in the full validation of
tau-imaging tracers, microPET has the potential to pro-
vide high-resolution dynamic images that will estimate
the content of tau aggregates via pharmacokinetic ana-
lysis. Finally, microPET can deliver crucial information
regarding tracer kinetics, requisite for both the develop-
ment of novel tau radiopharmaceuticals and in the con-
text of imaging analysis.
Clinical utility
It is expected that tau-imaging agents will contribute to
the early diagnosis of tauopathies. In addition, these
imaging agents will significantly expand our knowledge
regarding the propagation of tau protein in the human
brain as well as its relationships with clinical features of
the various tauopathies. Given the numerous drugs aiming
to halt the progression of tau pathology, it is also expectedthat these ligands will allow for the monitoring of treatment
effects of novel anti-tau therapies (see review Giacobini
et al. [39]). Yet, there remains a significant amount of
research to be conducted in order to establish the ad-
vantages and limitations of tau-imaging agents. Indeed,
well-controlled microPET studies in animal models are
necessary for the validation and development of tau
specific PET agents with less non-specific binding and
favorable kinetics (Table 1).
Concluding remarks
PET in tau transgenic models allows for longitudinal assess-
ment and thus is ideally suited for following tau pathology
progression and/or response to disease-modifying drugs.
Simultaneously, the use of the same animal for PET im-
aging and behavioral assessments eliminates the
between-subject variability and will provide key insights
on the role of tau in neurodegeneration and associated
cognitive decline. Finally, these results can rapidly be
translated to human research, delivering novel therapeutic
strategies, mechanistic insights, predictive models and
biomarkers.
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